Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
Clin. transl. oncol. (Print)
; Clin. transl. oncol. (Print);19(2): 219-226, feb. 2017. tab, graf
Article
en En
| IBECS
| ID: ibc-159455
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
Background/Aim. First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab. Patients and methods. This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months. Results. Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies. Conclusion. Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors (AU)
RESUMEN
No disponible
Buscar en Google
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Quimioterapia de Mantención
/
Bevacizumab
/
Supervivencia
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2017
Tipo del documento:
Article